Literature DB >> 10964166

mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours.

U Wulbrand1, G Remmert, P Zöfel, M Wied, R Arnold, H C Fehmann.   

Abstract

BACKGROUND: Insulin-like growth factors (IGF) and their corresponding receptors and binding proteins are important in carcinogenesis for several tumours, but their expression pattern in the functionally and biologically heterogeneous human neuroendocrine tumours of the gastroenteropancreatic tract is largely unknown.
MATERIALS AND METHODS: This study searched for the mRNA expression patterns of components of the IGF system: IGF-1 and IGF-2, IGF receptors 1 and 2 (IGF-1R, IGF-2R), IGF-binding proteins 1-6 (IGFBP1-6)) in the most frequent human gastroenteropancreatic neuroendocrine tumours (gastrinomas, insulinomas, tumours associated with carcinoid syndrome and functionally inactive tumours) employing reverse transcriptase-polymerase chain reaction (RT-PCR).
RESULTS: In the 37 tumour samples analysed (nine gastrinomas, 10 insulinomas, nine tumours associated with carcinoid syndrome and nine functionally inactive tumours) IGFBP-2 was found in all tumour samples while the IGFBP-1 was expressed only at low frequency (10-22%) among the four tumour types. The IGF-2R was predominantly expressed in gastrinomas. Among the four tumour types the expression of IGF-1R, IGF-2R and IGFBP-6 varied significantly. In addition, 12 pairs of significantly coexpressed IGF system components were detected (IGF-1 <--> IGF-1R, IGF-1 <--> IGF-2R, IGF-1 <--> IGFBP-3, IGF-1 <--> IGFBP-6, IGFBP-3 <--> IGF-1R, IGFBP-6 <--> IGF-1R, IGFBP-1 <--> IGF-2R, IGFBP-3 <--> IGF-2R, IGFBP-5 <--> IGF-2R, IGFBP-3 <--> IGFBP-5, IGFBP-3 <--> IGFBP-6, IGFBP-5 <--> IGFBP-6).
CONCLUSIONS: The described differences of the expression patterns of the IGF system components in neuroendocrine tumour subtypes suggest tumour type-dependent different pathways in tumour growth control by IGF system components.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964166     DOI: 10.1046/j.1365-2362.2000.00700.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  17 in total

1.  Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.

Authors:  Arvind Dasari; Alexandria Phan; Sanjay Gupta; Asif Rashid; Sai-Ching Jim Yeung; Kenneth Hess; Helen Chen; Emily Tarco; Huiqin Chen; Caimiao Wei; Kim Anh-Do; Daniel Halperin; Funda Meric-Bernstam; James Yao
Journal:  Endocr Relat Cancer       Date:  2015-04-21       Impact factor: 5.678

Review 2.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

3.  Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells.

Authors:  Ulrike Olszewski; Robert Zeillinger; Klaus Geissler; Gerhard Hamilton
Journal:  Lung Cancer (Auckl)       Date:  2010-09-04

Review 4.  Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms.

Authors:  Georgios Kyriakopoulos; Vasiliki Mavroeidi; Eleftherios Chatzellis; Gregory A Kaltsas; Krystallenia I Alexandraki
Journal:  Ann Transl Med       Date:  2018-06

5.  Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth.

Authors:  Christophe Couderc; Gilles Poncet; Karine Villaume; Martine Blanc; Nicolas Gadot; Thomas Walter; Florian Lepinasse; Valérie Hervieu; Martine Cordier-Bussat; Jean-Yves Scoazec; Colette Roche
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 6.  Genes involved in neuroendocrine tumor biology.

Authors:  Eva Hofsli
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 7.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

8.  A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.

Authors:  J R Strosberg; J A Chan; D P Ryan; J A Meyerhardt; C S Fuchs; T Abrams; E Regan; R Brady; J Weber; T Campos; L K Kvols; M H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

Review 9.  Drug Development in Neuroendocrine Tumors: What Is on the Horizon?

Authors:  Alejandro Garcia-Alvarez; Jorge Hernando Cubero; Jaume Capdevila
Journal:  Curr Treat Options Oncol       Date:  2021-03-30

10.  Generation and characterization of human insulin-releasing cell lines.

Authors:  Leticia Labriola; Maria G Peters; Karin Krogh; Iván Stigliano; Letícia F Terra; Cecilia Buchanan; Marcel C C Machado; Elisa Bal de Kier Joffé; Lydia Puricelli; Mari C Sogayar
Journal:  BMC Cell Biol       Date:  2009-06-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.